Povorcitinib, Incyte’s Oral JAK1 Inhibitor, Reduces Itch, Clears Lesions in PN
Incyte’s investigational oral Janus Kinase 1 (JAK1) inhibitor povorcitinib improves itch and clears skin in adults with prurigo nodularis (PN) by week 16, according to new data presented at the American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA. “In this phase 2 trial, Povorcitinib showed a very good efficacy on itch and […]